Pfizer Inc. (PFE)
Pfizer: Why Wall Street Habitually Overestimates Target Price
Pfizer Inc. (PFE) currently receives a buy rating from Wall Street, but I believe the rating is overoptimistic. Political uncertainties around 'TrumpRx' and 'Most-Favored-Nation' drug pricing models continue to threaten PFE's margins and valuation outlook. PFE's FWD P/E of 9.3x appears attractive on the surface, but is actually not once the multi-year earnings decline risks are factored in.
Why Pfizer Remains A Strong Buy In 2026
Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Its key anti-cancer drugs, Padcev, Lorbrena, and Talzenna, showed strong performance in Q4. Accordingly, sales of Talzenna rose 81.5% year-on-year to $49 million.
Why the Market Dipped But Pfizer (PFE) Gained Today
In the closing of the recent trading day, Pfizer (PFE) stood at $27.57, denoting a +1.06% move from the preceding trading day.
Income Investors Face a Hard Truth About Pfizer's Payout Safety
Pfizer (NYSE: PFE) is one of the most widely held dividend stocks among retirement investors.
This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven't Priced In
It's rare to get such a massive high-yielder that's also positioning itself for long-term growth.
Pfizer: Time To Buy The Turnaround
Pfizer remains a compelling value with a Strong Buy rating, driven by robust oncology pipeline progress and the Seagen acquisition. PFE's valuation is highly attractive, trading at a P/E of 8.35 and offering a 6.38% yield, with fair value estimated at $35 per share. Recent clinical wins in oncology and a promising obesity pipeline position PFE for long-term growth despite looming patent cliffs.
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial
Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year.
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease.
Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial
U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial.
Why Pfizer (PFE) Dipped More Than Broader Market Today
In the closing of the recent trading day, Pfizer (PFE) stood at $26.97, denoting a -1.61% move from the preceding trading day.
PFE Talzenna Combo Shows Strong Efficacy in Wider Prostate Cancer Use
Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic castration-sensitive prostate cancer patients.
PFE's Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.
